Status:

TERMINATED

Dose Response Study in Japanese Patients

Lead Sponsor:

AstraZeneca

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

30-80 years

Phase:

PHASE2

Brief Summary

This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients with type 2 d...

Eligibility Criteria

Inclusion

  • Provision of a written informed consent
  • Men or women who are \>=18 years of age
  • Female patients: postmenopausal, hysterectomized
  • Diagnosed with type 2 diabetes
  • Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral anti-diabetic agents

Exclusion

  • Type 1 diabetes
  • New York Heart Association heart failure Class III or IV
  • Treatment with chronic insulin
  • History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
  • History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
  • Creatinine levels above twice the normal range
  • Creatine kinase above 3 times the upper limit of normal
  • Received any investigational product in other clinical studies within 12 weeks
  • Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study

Key Trial Info

Start Date :

May 1 2004

Trial Type :

INTERVENTIONAL

End Date :

October 1 2005

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT00261417

Start Date

May 1 2004

End Date

October 1 2005

Last Update

April 22 2009

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

Research Site

Ashino, Japan

2

Research Site

Fuchu Keijinkai, Japan

3

Research Site

Fujimino, Japan

4

Research Site

Hijirino Koike, Japan